Difficulties in using 1,3-ß-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

RÁČIL Zdeněk KOCMANOVÁ Iva LENGEROVÁ Martina WEINBERGEROVÁ Barbora BUREŠOVÁ Lucie TOŠKOVÁ Martina WINTEROVÁ Jana TIMILSINA Shira RODRIGUEZ Isa MAYER Jiří

Year of publication 2010
Type Article in Periodical
Magazine / Source Journal of Medical Microbiology
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1099/jmm.0.019299-0
Field Oncology and hematology
Keywords invasive fungal disease; glucan; false positive results
Description We have evaluated the contribution of 1,3-ß-D-glucan (BG) assay for screening of invasive fungal diseases (IFI) in patients with hematological malignancies. Serum samples from patients at risk of IFI were collected twice a week and retrospectively tested using the BG assay. BG screening was performed on 1143 samples from 91 patients during 104 anticancer treatment cycles. Proven and probable cases of IFI occurred in 9 (8.7%) treatment cycles. Depending on the criterion of positivity used (1> 60 or 1> 80 pg/ml and 2> 60 or 2> 80 pg/ml) the sensitivity was 89%, 89%, 67% and 44%. Although the test was marked as positive in 82%, 68%, 54% and 45% of all the treatment cycles, in the majority of cases, these positivities were probably false. The major limit of the BG test was extremely low PPV (10% to 12%). We have analyzed mucositis, candida colonization, bacteremia, using antimicrobials, erythrocyte and thrombocyte filtered blood products, collecting tubes or sampling via venous catheters. Even though no factor is a major source of BG, it could at least partially influence BG assay performance. Thus, the BG detection has a limited usefulness as a screening method for invasive fungal infections in patients with hematological malignancies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info